1. Tell us about Solstar Pharma
Solstar Pharma is a specialty pharmaceutical company focused on the research & development of antimicrobial agents. Our company was founded because of a global health crisis that has been on the rise: the increase of antibiotic-resistant bacteria, known as “superbugs”. Solstar Pharma’s vision is to provide new and effective antimicrobial agents for the future.
2. What sets Solstar Pharma apart?
In order to combat antibiotic resistance, you must find innovative ways to target these superbugs. Solstar Pharma’s approach is to formulate a range of novel non-antibiotic antimicrobial agents while preventing a resistance to be gained by these bacteria. What sets us apart is that despite our agents differing in their composition, they utilize a different mechanism of action than conventional antibiotics in which superbugs have acquired resistance. Solstar Pharma’s method will have virtually no resistance thus eradicating all microorganisms, including resistant strains.
3. What does Solstar Pharma hope to accomplish over the next 5 years?
Our purpose is to expand our research capabilities beyond the development of drug formulation technology. Solstar Pharma hopes to achieve its main purpose to commercialize its formulated drugs against antibiotic-resistant pathogens while increasing its pipeline towards other unmet needs in indications such as cancer.
4. How has Exempt Edge software improved/impacted your day-to-day business?
Exempt Edge has completely changed and improved our workflow. The Issuer Edge software provides a single point of access to existing business information and sources thus eliminating the need to upkeep or maintain multiple databases. From organizing our investor’s information to distributing their statements within their assigned client portal, EE has helped reduce our time and costs associated to printing, shipping and managing numerous excel sheets. The Issuer Edge portal has helped us go paperless thus eliminating the need to send out hundreds of reports or statements which helps Solstar Pharma do its part on being an environmentally friendly business.
5. How has your experience been with the Exempt Edge team?
Our experience with the Exempt Edge team has been extremely pleasing. From the on-boarding team up to the support team, our experience has been flawless. The team knew exactly what system we wanted to implement for our investors and the team has been very responsive to our suggestions and needs. The EE team was very resourceful, and as soon as our investor portal went live, our experience was seamless and effortless allowing us to switch completely to paperless instantly.
6. What do you hope to see for the future of our industry?
Exempt Edge is heading in the right direction by giving us the opportunity to connect to various dealers or issuers in one seamless and secure ecosystem. We would hope to see in the future the implementation of various compliant legal document templates in order to reduce costs on legal fees while allowing investors to have access to their legal documents via the portal as well.
7. Anything else you’d like people to know?
We have and do recommend Exempt Edge to other businesses. It will improve your customer experience, reduce internal tasks, and enhance your workflow.
About Dennis Baltzis, PhD
Dr. Baltzis is currently the president of Solstar Pharma. Dr. Baltzis previously worked as an oncology clinical research associate at Covance, and as an Oncology Clinical Research Coordinator at the Clinical Research Unit of the Jewish General Hospital, Montreal, Canada. He monitored, managed and coordinated various phase I-III Pharmaceutical oncology clinical trials throughout Canada and the United States. Dr. Baltzis obtained both his B. Sc. in Microbiology and Immunology, and his PhD degree in Experimental Medicine specializing in molecular oncology from McGill University. He then pursued his post-doctoral training in Immunology at the University of Dundee, Scotland working as a Medical Research Council scientific advisor reporting to pharmaceutical companies. His research findings provided information that helped shape research and development policies regarding drug discovery for major pharmaceutical companies.